Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

cGVHD Clinical Trial

Official title:
Study on the Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD) of the Liver Following Allogeneic Hematopoietic Stem Cell Transplantatio

Status Not yet recruiting

Clinical Trial Summary

The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation. After obtaining informed consent, the patients will be randomly assigned to either the Anti-CD25 rhMAb treatment group or the traditional treatment group. The objective is to assess the effectiveness and safety of Anti-CD25 rhMAb in the treatment of severe chronic GVHD affecting the liver.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

cGVHD

Clinical Trial Details

NCT number	NCT06364319
Study type	Interventional
Source	Peking University People's Hospital
Contact
Status	Not yet recruiting
Phase	Phase 4
Start date	April 15, 2024
Completion date	June 30, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01221766` - Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease	N/A
Recruiting	`NCT06186804` - A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)	Phase 2
Recruiting	`NCT06244628` - Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD	Phase 3
Withdrawn	`NCT05604742` - Belimumab for Treatment of cGVHD Following Allo-HCT	Phase 1/Phase 2
Recruiting	`NCT05214066` - Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT	Phase 2
Recruiting	`NCT05919511` - Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease